List of Excipients in Branded Drug LANREOTIDE ACETATE

Generic Drugs Containing LANREOTIDE ACETATE

Company	Ingredient	NDC	Excipient
Cipla USA Inc	lanreotide acetate	69097-907	ACETIC ACID
Cipla USA Inc	lanreotide acetate	69097-907	WATER
EXELAN PHARMACEUTICALS INC	lanreotide acetate	76282-718	ACETIC ACID

What are the Most Frequently-Used Excipients in LANREOTIDE ACETATE?

# Of NDCs	Excipient
2	ACETIC ACID
2	WATER

Lanreotide Acetate Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Lanreotide acetate is a long-acting somatostatin analog marketed primarily as Somatuline Depot and Somatuline Autogel by Ipsen. Its commercial value depends less on novel excipient composition than on maintaining peptide stability in a highly concentrated, ready-to-use subcutaneous depot product. The principal opportunities are generic or hybrid-product development, improved syringe and autoinjector systems, lower-cost manufacturing, extended temperature stability, and regional supply of pharmaceutical-grade excipients and packaging components.

The marketed formulation uses a short excipient system centered on water for injection and acetic acid. That simplicity reduces formulation differentiation but creates demanding requirements for peptide aggregation control, container compatibility, sterility, viscosity, particle control, and device performance.

What excipients are used in lanreotide acetate injection?

The US Somatuline Depot formulation contains lanreotide acetate in a sterile aqueous solution. The inactive ingredients identified in the FDA prescribing information are water for injection and acetic acid.[1]

Component	Function	Commercial relevance
Lanreotide acetate	Active peptide drug substance	Requires control of aggregation, degradation, potency, and impurities
Water for injection	Primary vehicle	Must meet injectable quality, bioburden, endotoxin, and conductivity specifications
Acetic acid	pH adjustment and formulation control	Influences solubility, peptide stability, injection tolerability, and release profile

Somatuline Depot is supplied in 60 mg, 90 mg, and 120 mg strengths in a 0.5 mL prefilled syringe. The high drug load and low injection volume are central product attributes.[1]

Why is acetic acid important in lanreotide formulations?

Acetic acid provides control of the formulation environment without introducing a multi-component buffer system. For a peptide product, pH affects:

• Solubility and supersaturation behavior
• Electrostatic interactions between peptide molecules
• Aggregation and particle formation
• Chemical degradation pathways
• Syringe and elastomer compatibility
• Local tolerability after subcutaneous administration

The commercial advantage of a limited excipient system is a smaller regulatory and manufacturing burden. The disadvantage is a narrower operating window. Small changes in pH, ionic strength, peptide concentration, or processing temperature can affect product performance.

How does the lanreotide depot formulation work?

Lanreotide Depot uses a concentrated aqueous peptide formulation that forms a prolonged-release depot after subcutaneous administration. The product is administered as a deep subcutaneous injection, usually at 28-day intervals for approved indications such as acromegaly and certain gastroenteropancreatic neuroendocrine tumors.[1,2]

The formulation strategy differs from microsphere-based peptide products. It does not rely primarily on a biodegradable polymer carrier. Instead, the product’s concentration, physical state, peptide interactions, and post-injection depot behavior control release.

What formulation attributes must a competitor match?

A follow-on product must address more than the nominal 60 mg, 90 mg, or 120 mg strength. Important performance attributes include:

1. Peptide concentration and delivered dose.
2. Solution clarity and visible-particle profile.
3. Subcutaneous injectability.
4. Syringeability at refrigerated and administration temperatures.
5. Release duration over the dosing interval.
6. Peptide-related impurity profile.
7. Aggregation and subvisible-particle levels.
8. Container closure integrity.
9. Device delivery accuracy.
10. Stability throughout the labeled storage period.

For an ANDA or hybrid application, formulation sameness alone may not establish equivalent clinical performance if the product has materially different physical characteristics, release behavior, or delivery-device mechanics.

What excipient strategies are available for lanreotide acetate?

Strategy 1: Preserve the commercial excipient system

The lowest-risk approach is to reproduce the water-for-injection and acetic-acid system, subject to regulatory requirements and demonstration of pharmaceutical equivalence.

Advantages include:

• Limited excipient toxicology burden
• Familiar regulatory precedent
• Simplified manufacturing
• Lower risk of new immunogenicity or local-tolerability issues
• Easier comparison with the reference product

The principal challenge is that the formulation may be protected by manufacturing know-how, process controls, device specifications, or formulation-related patent claims even where the ingredient list is simple.

Strategy 2: Optimize pH and acid concentration

A developer can investigate the concentration of acetic acid and the operating pH range while retaining the same general formulation concept. This may improve:

• Chemical stability
• Resistance to aggregation
• Injection force
• Storage robustness
• Compatibility with the prefilled syringe

The strategy has a narrow commercial path. A formulation that departs too far from the reference product may require additional clinical or comparative evidence, particularly if release behavior or local tolerability changes.

Strategy 3: Introduce a stabilizing excipient

Potential stabilizer classes include sugars, polyols, amino acids, surfactants, and alternative buffer systems. These materials can reduce interfacial stress or peptide aggregation, but they introduce new risks.

Excipient class	Potential benefit	Primary risk
Sugars and polyols	May reduce aggregation and protect during temperature excursions	Increased viscosity or osmolality
Amino acids	Can modify peptide interactions and aggregation	New impurity and compatibility profile
Polysorbates	May reduce surface adsorption and agitation stress	Oxidative degradation, peroxide formation, particles
Poloxamers	Interfacial protection	Viscosity and extractables concerns
Phosphate or acetate buffers	pH control	Altered peptide solubility, ionic strength, and depot behavior
Antioxidants or chelators	May limit oxidative pathways	New regulatory and tolerability burden

For a commercial follow-on, additional excipients are most attractive when they solve a clear product problem, such as improved room-temperature stability, reduced injection force, or compatibility with an autoinjector.

Strategy 4: Develop a lyophilized or reconstituted presentation

A lyophilized lanreotide product could improve long-term peptide stability, but it would change the user experience and may eliminate key commercial advantages of the reference product. Reconstitution introduces:

• A second handling step
• Dose-preparation risk
• Reconstitution-time requirements
• Potential variability in concentration
• Additional vial, stopper, and diluent components

This approach is more suitable for markets where cold-chain distribution is difficult or where a lower-cost presentation has a clear purchasing advantage.

Strategy 5: Use an alternative long-acting delivery platform

A polymeric microsphere, in situ gel, implant, or depot suspension could provide monthly or extended dosing. These platforms create a larger development opportunity but also increase regulatory complexity.

They may require characterization of:

• In vitro release
• In vivo pharmacokinetics
• Local tissue response
• Burst release
• Residual solvents
• Polymer degradation
• Dose uniformity
• Injection-site tolerability

Such products are more likely to require a 505(b)(2) application in the United States or a hybrid application in Europe than a straightforward generic pathway.

What are the main manufacturing barriers for lanreotide acetate?

Lanreotide is a peptide drug substance. Manufacturing and formulation controls must limit chemical and physical degradation from API synthesis through final-device filling.

Peptide handling and aggregation

Relevant risks include deamidation, oxidation, hydrolysis, oligomerization, adsorption, and particulate formation. The highest-risk operations generally include:

• High-shear mixing
• Prolonged hold times
• Repeated temperature cycling
• Air-liquid interfacial exposure
• Contact with incompatible elastomers or lubricants
• Filling into silicone-oil-coated syringes
• Terminal sterilization attempts

The product is supplied as a sterile injectable formulation, so aseptic processing and sterile filtration strategy are central to the control system. The formulation must be filterable without excessive peptide adsorption or loss of potency.

Prefilled-syringe compatibility

The syringe is part of the product performance system. Key issues include:

• Silicone oil migration
• Tungsten residues from syringe manufacture
• Plunger movement and break-loose force
• Needle protection integrity
• Extractables and leachables
• Long-term interaction with the barrel and stopper
• Delivery-volume accuracy

A competitor that uses the same nominal excipients but a different syringe system may generate a different particulate, injection-force, or stability profile.

Viscosity and injection force

High peptide concentration can increase viscosity and injection force. This limits the choice of excipients and may restrict the use of narrow-gauge needles or autoinjectors.

Commercially valuable improvements include:

• Lower injection force
• Shorter injection time
• Reduced needle size
• Better cold-product delivery
• Easier administration by patients or caregivers

These improvements can support device differentiation even when the active formulation is similar to the reference product.

What commercial opportunities exist for lanreotide acetate excipients?

Pharmaceutical-grade acetic acid

Acetic acid is a commodity chemical, but injectable use requires controlled specifications, validated supply, low impurities, and suitable manufacturing documentation. Suppliers can compete on:

• Low-metal grades
• Low-peroxide and low-organic-impurity profiles
• GMP documentation
• Regional supply continuity
• Change-control discipline
• Small-volume development support

The value per unit is low, but the switching cost rises once the excipient is embedded in a validated commercial process.

Water-for-injection systems

Water for injection is not a differentiated formulation excipient, but water-system design can influence operating cost, microbial control, and site qualification. Opportunities include:

• Modular WFI generation
• Continuous monitoring
• Single-use formulation systems
• Regional fill-finish platforms
• Lower-energy water purification
• Integrated aseptic processing

Syringes and delivery components

The largest excipient-adjacent opportunity is likely in packaging and delivery rather than in the acid-water formulation itself. Suppliers can target:

• Low-silicone or silicone-free syringes
• Low-friction plungers
• Autoinjector-compatible barrels
• High-viscosity injectable systems
• Improved needle shields
• Device systems optimized for deep subcutaneous injection

A successful device must preserve delivery accuracy and stability while reducing patient burden.

Stability-enhancing formulations

A formulation that remains stable during controlled temperature excursions could reduce distribution costs and expand access in markets with limited cold-chain infrastructure. The commercial hurdle is demonstrating that stability gains do not alter depot behavior, local tolerability, or peptide impurity levels.

Regional generic and hybrid products

Lanreotide has a relatively specialized market, which can support regional opportunities where:

• Acromegaly treatment access is expanding
• Neuroendocrine tumor diagnosis is increasing
• Public procurement favors lower-cost alternatives
• Local fill-finish capacity is available
• The reference product has limited distribution

A low-cost product must still solve the manufacturing problem of concentrated peptide filling and reliable monthly delivery. A simple excipient list does not make the product simple to manufacture.

What is the FDA regulatory status of lanreotide acetate?

Somatuline Depot is approved in the United States under NDA 022074 for acromegaly and specific gastroenteropancreatic neuroendocrine tumor indications.[1] The product is regulated as a peptide drug product, not as a monoclonal antibody or other biologic for purposes of the US biosimilar pathway.

Is a lanreotide biosimilar pathway available?

No conventional biosimilar pathway is generally expected for lanreotide acetate. A follow-on developer would more likely pursue:

• An ANDA, if the product meets applicable generic-drug requirements
• A 505(b)(2) application, if formulation, device, route, release, or clinical data differ materially
• A regional generic or hybrid application outside the United States

The regulatory classification depends on the product’s formulation, dosage form, reference-product status, and proposed labeling.

What must be demonstrated for a follow-on product?

A development program would typically need to establish:

• Pharmaceutical equivalence
• Assay and impurity comparability
• Sterility and endotoxin control
• Stability
• Container-closure integrity
• Injection performance
• Device functionality
• Comparative pharmacokinetics where required
• Comparable release or depot behavior
• Adequate clinical justification for any formulation difference

What patents protect lanreotide acetate products?

Lanreotide intellectual property has historically focused on the peptide, long-acting formulations, manufacturing methods, and delivery systems. The commercial risk is therefore broader than the inactive-ingredient list.

Relevant patent categories include:

Patent category	Potential protected subject matter
Active pharmaceutical ingredient	Lanreotide composition, salts, purity, or crystalline forms
Depot formulation	Concentration, pH, physical state, and prolonged-release behavior
Manufacturing	Peptide synthesis, purification, formulation, and aseptic filling
Device	Prefilled syringe, needle system, and administration mechanism
Method of use	Acromegaly and neuroendocrine tumor treatment regimens
Process controls	Particle reduction, aggregation control, and stability methods

Patent expiration and enforceability must be assessed separately by jurisdiction. US Orange Book listings, European supplementary protection certificates, national formulation patents, and device rights can produce different entry dates. A generic developer may face residual formulation or device barriers even after basic active-ingredient rights expire.

What Orange Book issues affect generic entry?

For a US ANDA applicant, the relevant questions are:

• Which patents are listed for NDA 022074?
• Which listed patents have unexpired claims?
• Are the claims directed to the drug substance, formulation, method of use, or device?
• Can the applicant submit a Paragraph IV certification?
• Can the applicant carve out patented indications?
• Does the reference product’s presentation create a device or labeling obstacle?

A Paragraph IV challenge can create litigation risk and a potential 30-month stay, depending on the listing, notice, and litigation sequence under the Hatch-Waxman framework.[3]

When does lanreotide lose exclusivity?

Lanreotide exclusivity is not determined by one global date. The relevant timing depends on:

• US patent expiration
• Regulatory exclusivity
• Pediatric exclusivity
• Supplementary protection certificates
• National formulation and device patents
• Litigation settlements
• Market-specific approval requirements

The practical loss-of-exclusivity date is the earliest date on which a legally approvable and commercially viable competing product can enter. That date can differ from the expiration of the earliest active-ingredient patent.

No widely established lanreotide biosimilar entry wave currently defines the market. Competitive entry is more likely to arise from generic, hybrid, or locally approved depot products.

Which companies are challenging lanreotide products?

The commercial market remains concentrated around Ipsen’s Somatuline franchise. Publicly visible competition is more fragmented than in high-volume oral medicines because the product requires peptide manufacturing, sterile filling, specialized delivery, and monthly depot performance.

Potential competitors include:

• Generic injectable manufacturers
• Peptide API suppliers
• Regional specialty pharmaceutical companies
• Contract development and manufacturing organizations
• Device companies developing prefilled syringes or autoinjectors
• Developers of alternative somatostatin analog depots

Octreotide LAR is the most relevant therapeutic comparator, although it is not a direct formulation substitute. Its microsphere-based depot system has different manufacturing, administration, and patent considerations.[4]

How does lanreotide compare with octreotide LAR?

Attribute	Lanreotide Depot	Octreotide LAR
Drug class	Somatostatin analog	Somatostatin analog
Typical depot concept	Concentrated aqueous peptide depot	Polymer microsphere depot
Administration	Deep subcutaneous injection	Intramuscular injection
Commercial brand	Somatuline Depot	Sandostatin LAR Depot
Excipient strategy	Limited aqueous system	Polymer-based delivery system with reconstitution components
Manufacturing challenge	Concentrated peptide stability and syringe delivery	Microsphere production, encapsulation, release control
Device opportunity	Prefilled syringe and autoinjector	Reconstitution and injection workflow
Follow-on pathway	Generic or hybrid	Generic, hybrid, or complex injectable pathway

Lanreotide’s lower-volume, prefilled presentation can create a device-based commercial advantage. Octreotide LAR’s polymer microsphere system creates a different technical barrier and may support greater formulation differentiation.

What generic launch scenarios exist for lanreotide acetate?

Scenario 1: Same-formulation prefilled syringe

This is the most direct competitive model. The developer preserves the basic excipient system and focuses on:

• API cost
• Yield improvement
• Automated filling
• Syringe procurement
• Device equivalence
• Regional distribution

This model has the lowest formulation risk but the highest exposure to patent, device, and reference-product comparability issues.

Scenario 2: Hybrid product with improved delivery

A developer could use a modified syringe or autoinjector while keeping the formulation substantially similar. Commercial value would depend on lower injection force, easier administration, or improved adherence.

Scenario 3: Alternative depot formulation

A new depot system could offer longer dosing intervals, lower injection burden, or reduced cold-chain requirements. It would face greater clinical, regulatory, and manufacturing costs.

Scenario 4: Regional low-cost presentation

A vial or alternative presentation could compete in tender-driven markets. The product would trade some convenience for lower packaging and device costs. This strategy is more viable where procurement price outweighs patient preference for a prefilled syringe.

How strong is the lanreotide patent estate?

The estate is strongest where formulation, manufacturing, device, and method-of-use rights overlap. A simple excipient list does not eliminate patent risk because claims may cover concentration ranges, pH, depot behavior, process conditions, or delivery systems.

The strongest commercial defenses are likely to be:

• Valid claims covering the long-acting formulation
• Manufacturing know-how that is difficult to reproduce
• Reliable prefilled-device performance
• Regulatory complexity associated with a peptide depot
• Physician and patient familiarity with the reference presentation

The weaker areas are commodity excipient supply and basic aqueous formulation concepts that lack meaningful claim scope. The decisive issue for a challenger is whether it can reproduce the product’s clinical and delivery performance without practicing enforceable formulation or device claims.

Key Takeaways

• Lanreotide acetate injection uses a highly limited excipient system, primarily water for injection and acetic acid.
• The principal technical challenge is concentrated peptide stability, not excipient novelty.
• Aggregation, subvisible particles, syringe compatibility, injection force, and depot behavior are critical quality attributes.
• The strongest commercial opportunities are in generic or hybrid products, prefilled syringes, autoinjectors, fill-finish efficiency, and improved temperature stability.
• Lanreotide is a peptide drug and is not expected to follow the conventional monoclonal-antibody biosimilar pathway.
• Generic entry may require an ANDA or 505(b)(2) application in the United States, depending on formulation and device differences.
• Patent risk can extend beyond the active ingredient to depot formulation, manufacturing, device, and method-of-use claims.
• Octreotide LAR is the principal therapeutic comparator but has a materially different polymer-microsphere formulation and administration model.
• Acetic acid and WFI are low-value commodities individually; validated injectable supply and change-control reliability create the commercial value.
• The most defensible follow-on strategy combines formulation similarity with differentiated delivery, manufacturing cost, or storage performance.

FAQs About Lanreotide Acetate Excipient and Commercial Strategy

Can lanreotide acetate be formulated without acetic acid?

A developer can investigate alternative pH-adjustment systems, but removing acetic acid may change solubility, aggregation, injection tolerability, and depot behavior. The regulatory pathway would depend on the extent of formulation and performance differences.

Is lanreotide acetate suitable for an autoinjector?

Potentially, but the concentrated peptide formulation may create high injection force. Autoinjector feasibility depends on viscosity, syringe dimensions, needle gauge, injection time, temperature, and dose-delivery accuracy.

Does lanreotide require a preservative?

The commercial prefilled syringe is a single-dose sterile presentation and does not depend on a multidose preservative system. Adding a preservative would create unnecessary compatibility and tolerability questions unless the product were redesigned as a multidose presentation.

What is the largest cost driver in a lanreotide generic?

The largest costs are likely to arise from peptide API production, yield and impurity control, aseptic filling, prefilled-syringe components, device qualification, and regulatory comparability work. Acetic acid and WFI are comparatively minor cost elements.

Could a lanreotide product use a longer-acting depot system?

Yes, but a longer-acting polymer, implant, or in situ gel would likely create a new product-development program rather than a simple generic. The developer would need to characterize release, local tissue effects, dose control, manufacturing reproducibility, and clinical performance.

References

1. U.S. Food and Drug Administration. (2023). Somatuline Depot (lanreotide acetate) injection: Prescribing information. Ipsen Biopharmaceuticals, Inc.

2. European Medicines Agency. (2023). Somatuline Autogel: EPAR product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Sandostatin LAR Depot (octreotide acetate) for injectable suspension: Prescribing information. Novartis Pharmaceuticals Corporation.

5. Ipsen. (2024). Universal registration document and annual financial report 2023. Ipsen S.A.